258 related articles for article (PubMed ID: 26487696)
1. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696
[TBL] [Abstract][Full Text] [Related]
2. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
3. The
Hong T; Luo M; Liu Q
Genet Test Mol Biomarkers; 2020 Apr; 24(4):181-187. PubMed ID: 32202925
[No Abstract] [Full Text] [Related]
4. TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients.
Matsuguma M; Yujiri T; Yamamoto K; Kajimura Y; Tokunaga Y; Tanaka M; Tanaka Y; Nakamura Y; Tanizawa Y
Int J Hematol; 2019 Dec; 110(6):690-698. PubMed ID: 31571131
[TBL] [Abstract][Full Text] [Related]
5. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms.
Jäger R; Harutyunyan AS; Rumi E; Pietra D; Berg T; Olcaydu D; Houlston RS; Cazzola M; Kralovics R
Am J Hematol; 2014 Dec; 89(12):1107-10. PubMed ID: 25196853
[TBL] [Abstract][Full Text] [Related]
6. TERT rs2736100 genotypes are associated with differential risk of myeloproliferative neoplasms in Swedish and Chinese male patient populations.
Dahlström J; Liu T; Yuan X; Saft L; Ghaderi M; Wei YB; Lavebratt C; Li P; Zheng C; Björkholm M; Xu D
Ann Hematol; 2016 Oct; 95(11):1825-32. PubMed ID: 27561898
[TBL] [Abstract][Full Text] [Related]
7. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
8. MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients.
Trifa AP; Bănescu C; Bojan AS; Voina CM; Popa Ș; Vișan S; Ciubean AD; Tripon F; Dima D; Popov VM; Vesa ȘC; Andreescu M; Török-Vistai T; Mihăilă RG; Berbec N; Macarie I; Coliţă A; Iordache M; Cătană AC; Farcaș MF; Tomuleasa C; Vasile K; Truică C; Todincă A; Pop-Muntean L; Manolache R; Bumbea H; Vlădăreanu AM; Gaman M; Ciufu CM; Popp RA
Am J Hematol; 2018 Jan; 93(1):100-106. PubMed ID: 29047144
[TBL] [Abstract][Full Text] [Related]
9. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.
Tapper W; Jones AV; Kralovics R; Harutyunyan AS; Zoi K; Leung W; Godfrey AL; Guglielmelli P; Callaway A; Ward D; Aranaz P; White HE; Waghorn K; Lin F; Chase A; Baxter EJ; Maclean C; Nangalia J; Chen E; Evans P; Short M; Jack A; Wallis L; Oscier D; Duncombe AS; Schuh A; Mead AJ; Griffiths M; Ewing J; Gale RE; Schnittger S; Haferlach T; Stegelmann F; Döhner K; Grallert H; Strauch K; Tanaka T; Bandinelli S; Giannopoulos A; Pieri L; Mannarelli C; Gisslinger H; Barosi G; Cazzola M; Reiter A; Harrison C; Campbell P; Green AR; Vannucchi A; Cross NC
Nat Commun; 2015 Apr; 6():6691. PubMed ID: 25849990
[TBL] [Abstract][Full Text] [Related]
10. The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis.
Zerjavic K; Zagradisnik B; Lokar L; Krasevac MG; Vokac NK
Thromb Res; 2013 Aug; 132(2):e86-93. PubMed ID: 23845539
[TBL] [Abstract][Full Text] [Related]
11. A TET2 rs3733609 C/T genotype is associated with predisposition to the myeloproliferative neoplasms harboring JAK2(V617F) and confers a proliferative potential on erythroid lineages.
Shen XH; Sun NN; Yin YF; Liu SF; Liu XL; Peng HL; Dai CW; Xu YX; Deng MY; Luo YY; Zheng WL; Zhang GS
Oncotarget; 2016 Feb; 7(8):9550-60. PubMed ID: 26843622
[TBL] [Abstract][Full Text] [Related]
12. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
[TBL] [Abstract][Full Text] [Related]
13. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.
Hinds DA; Barnholt KE; Mesa RA; Kiefer AK; Do CB; Eriksson N; Mountain JL; Francke U; Tung JY; Nguyen HM; Zhang H; Gojenola L; Zehnder JL; Gotlib J
Blood; 2016 Aug; 128(8):1121-8. PubMed ID: 27365426
[TBL] [Abstract][Full Text] [Related]
14. Risk-Reducing Genetic Variant of Wilms Tumor 1 Gene rs16754 in Korean Patients With BCR-ABL1-Negative Myeloproliferative Neoplasm.
Kim N; Kim IS; Chang CL; Kang JE; Lee EY; Shin HJ
Ann Lab Med; 2015 May; 35(3):348-51. PubMed ID: 25932444
[TBL] [Abstract][Full Text] [Related]
15. The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma.
Yuan X; Cheng G; Yu J; Zheng S; Sun C; Sun Q; Li K; Lin Z; Liu T; Li P; Xu Y; Kong F; Bjorkholm M; Xu D
Oncotarget; 2017 Apr; 8(14):23120-23129. PubMed ID: 28416747
[TBL] [Abstract][Full Text] [Related]
16. The TERT locus genotypes of rs2736100-CC/CA and rs2736098-AA predict shorter survival in renal cell carcinoma.
Ma R; Liu C; Lu M; Yuan X; Cheng G; Kong F; Lu J; Strååt K; Björkholm M; Ma L; Xu D
Urol Oncol; 2019 May; 37(5):301.e1-301.e10. PubMed ID: 30738744
[TBL] [Abstract][Full Text] [Related]
17. Germline variations at
Chiang YH; Chang YC; Lin HC; Huang L; Cheng CC; Wang WT; Cheng HI; Su NW; Chen CG; Lin J; Chang YF; Chang MC; Hsieh RK; Chou WC; Lim KH; Kuo YY
Oncotarget; 2017 Sep; 8(44):76204-76213. PubMed ID: 29100304
[TBL] [Abstract][Full Text] [Related]
18. The TERT rs2736100 polymorphism increases cancer risk: A meta-analysis.
Li H; Xu Y; Mei H; Peng L; Li X; Tang J
Oncotarget; 2017 Jun; 8(24):38693-38705. PubMed ID: 28418878
[TBL] [Abstract][Full Text] [Related]
19. Genetic association between germline JAK2 polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese population: a case-control study.
Koh SP; Yip SP; Lee KK; Chan CC; Lau SM; Kho CS; Lau CK; Lin SY; Lau YM; Wong LG; Au KL; Wong KF; Chu RW; Yu PH; Chow EY; Leung KF; Tsoi WC; Yung BY
BMC Genet; 2014 Dec; 15():147. PubMed ID: 25526816
[TBL] [Abstract][Full Text] [Related]
20. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.
Martinelli I; De Stefano V; Carobbio A; Randi ML; Santarossa C; Rambaldi A; Finazzi MC; Cervantes F; Arellano-Rodrigo E; Rupoli S; Canafoglia L; Tieghi A; Facchini L; Betti S; Vannucchi AM; Pieri L; Cacciola R; Cacciola E; Cortelezzi A; Iurlo A; Pogliani EM; Elli EM; Spadea A; Barbui T
Am J Hematol; 2014 Nov; 89(11):E200-5. PubMed ID: 25042466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
